Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancer: towards biomarker-driven therapies?

Transl Lung Cancer Res. 2025 Feb 28;14(2):328-333. doi: 10.21037/tlcr-24-966. Epub 2025 Feb 24.

Authors

M Benthe Muntinghe-Wagenaar¹, T Jeroen N Hiltermann¹

Affiliation

¹ Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

No abstract available

Keywords: Immune checkpoint inhibition; biomarker; non-small cell lung cancer (NSCLC); programmed death-ligand 1 (PD-L1).

Publication types

Editorial
Comment